HomeROIV • NASDAQ
add
Roivant Sciences Ltd
Previous close
$10.74
Day range
$10.15 - $10.83
Year range
$9.76 - $13.06
Market cap
7.40B USD
Avg Volume
4.06M
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
In the news
Financials
Income Statement
Revenue
Net income
| (USD) | Dec 2024info | Y/Y change |
|---|---|---|
Revenue | 9.02M | -42.05% |
Operating expense | 132.34M | 31.07% |
Net income | 169.38M | -96.68% |
Net profit margin | 1.88K | -94.26% |
Earnings per share | -0.20 | 4.01% |
EBITDA | -261.54M | -42.81% |
Effective tax rate | 10.90% | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Dec 2024info | Y/Y change |
|---|---|---|
Cash and short-term investments | 5.15B | -22.85% |
Total assets | 5.79B | -20.79% |
Total liabilities | 256.38M | -64.79% |
Total equity | 5.54B | — |
Shares outstanding | 713.55M | — |
Price to book | 1.49 | — |
Return on assets | -10.98% | — |
Return on capital | -11.69% | — |
Cash Flow
Net change in cash
| (USD) | Dec 2024info | Y/Y change |
|---|---|---|
Net income | 169.38M | -96.68% |
Cash from operations | -207.25M | 1.52% |
Cash from investing | 454.07M | -91.32% |
Cash from financing | -272.95M | -215.34% |
Net change in cash | -27.20M | -100.52% |
Free cash flow | -303.56M | -321.65% |
About
Roivant Sciences Ltd. is an American multinational healthcare company focused on applying technology to drug development and building subsidiary life sciences and health technology companies. It was founded in 2014 by Vivek Ramaswamy and is currently headed by CEO Matt Gline. Roivant maintains its headquarters in New York City as well as major offices in the biotech hubs of Boston and Basel. Wikipedia
CEO
Founded
Apr 7, 2014
Website
Employees
908
